两种小剂量利妥昔单抗治疗方案治疗原发免疫性血小板减少症疗效比较

目的 比较两种小剂量利妥昔单抗治疗方案治疗成人原发免疫性血小板减少症(ITP)的疗效。方法 51例ITP患者非随机分为两组:A组31例患者利妥昔单抗用量为100 m g/周,连续4周;B组20例患者利妥昔单抗用量为375 mg/m2,只用1次。结果 A组:总有效(OR)率和完全反应(CR)率分别为58％和29％,中位反...

Efficacy and safety of two different low-dose rituximab regimens for Chinese adult patients with immune thrombocytopenia

Objective To compare the efficacy of two different regimens of low doses rituximab for the treatment of adult patients with immune thrombocytopenia (ITP). Methods Fifty-one patients were enrolled in this study and was non-randomly assigned to receive 100 mg rituximab weekly for 4 weeks (group A, 31 cases) or a single dose of 375 mg/m2 rituximab ( group B, 20 cases). Results For group A: Overall and complete response( OR and CR) rates were 58％ and 29％, respectively. In responders, the median time to response was 42 ( 10 - 101 ) days, with a median follow-up time of 15( 10 - 16) months, 3 of 18 responders ( 17％ ) relapsed. For group B: OR and CR rates were 50％ and 35％, respectively. In responders, the median time to response was 35 (18 -108) days, with a median follow-up time of 13 (6 - 17) months, 1 of 9 responders ( 11％ ) relapsed. No significant difference in the OR, CR, the relapse rate and relapse free survival was observed in patients between the two groups. Conclusion The low dose rituximab regimen( 100 mg weekly for 4 weeks or a single close of 375 mg/m2 ) may be a useful alternative therapy in patients with ITP.